|
Special Issue on Treatment Tolerability Research in Cancer
|
A special issue in Cancer titled “Analyzing and Reporting the Impact of Cancer Therapies on Tolerability: Findings from the NCI Tolerability Consortium” has been published and is available via open access.
The special issue features innovative approaches to measuring tolerability using both clinician- and patient-reported outcomes, and much more.
Read the Special Issue.
|
|
 |
Military Aviators Cancer Study
|
The research community can now request data and serum samples from the Military Aviators Cancer Study (MACS) by submitting a project proposal using the Cancer Data Access System website. MACS investigates cancer incidence among military aviators and aviation support personnel.
Learn more about MACS on the Cancer Data Access System Website.
|
|
 |
|
|
Environmental Exposure-Related Risk in Skin Cancer Webinar
|
Thursday, January 22
1:00-2:30 p.m. ET (Virtual)
Advance registration required
Learn about environmental exposures and skin cancer risk at this webinar hosted by the NCI’s Division of Cancer Prevention (DCP) Environmental Sciences and Cancer Prevention Working Group.
Hunter Shain, P.h.D., (left) will discuss molecular effects of indoor tanning, and Lei Wei, Ph.D., (right) will discuss UV-induced mutations and cancer.
For more details, see the Meeting Agenda.
|
|
 |
Building Bridges in Cancer Symptom Science: Impact of Cancer and Cancer Treatment on Bone Health
|
Thursday, January 29
2:00-3:00 p.m. ET (Virtual)
Advance registration required
Please join us at our next Building Bridges in Cancer Symptom Science Webinar on the impact of cancer and cancer treatment on bone health. Theresa A Guise, M.D., FASBMR, (left) will discuss bone health and cancer treatment-induced bone destruction, while Xiang Zhang, Ph.D., (right) will review metastasis and bone fragility.
Speakers:
Theresa A. Guise, M.D., FASBMR
M.D. Anderson Cancer Center
Cancer Prevention Research Institute of Texas
Xiang Zhang, Ph.D.
Baylor College of Medicine
Learn more about the Building Bridges in Cancer Symptom Science Webinar Series.
|
|
 |
DCP Early Career Scientist Spotlight Research Seminar Series
Join us for two upcoming virtual talks from early career scientists who are advancing research in areas supported by DCP.
Thursday, February 12
11:00 a.m.-Noon ET
Advance registration required
Claire C. Conley, Ph.D., assistant professor, Georgetown University (left), will give a talk on “Symptom Management Needs and Interventions Among Individuals Living with Metastatic Cancer,” and Sarah Mazzili, Ph.D., assistant professor of medicine, Boston University (right), will give a talk on "Molecular Alterations Associated with Airway Injury & Lung Squamous Precancerous Lesions to Inform Early Lung Cancer Intervention."
|
|
Monday, February 23
1:00-2:00 p.m. ET
Advance registration required
Joshua Demb, Ph.D., M.P.H., assistant professor
in residence, UCSan Diego (left), will give a talk
on “Early Onset Colorectal Cancer Detection:
Two Viable Strategies,” and Preshita Desai, B., Pharm., Ph.D., assistant professor at Western University of Health Sciences (right), will give a talk on "The Perfect Pair: Engineering Drug Synergy and Nano Drug Delivery Precision for Smarter Cancer Prevention."
Learn more about the Early Career Scientist Research Seminar Series.
|
|
 |
|
|
Notice of Funding Opportunities (NOFOs) |
|
Assay Validation of High-Quality Markers for Clinical Studies in Cancer
|
NCI invites applications to support the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO supports investigator-initiated research for both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by NCI.
PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed)
PAR-25-075 (UH3 Clinical Trials Not Allowed)
Close date: October 14, 2026
|
|
 |
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research
Through this NOFO, NCI encourages applications that support the biochemical and genetic analyses of cancer risk, and the discovery and validation of early detection biomarkers. Selected applicants will use the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.
PAR-25-248 (U01 Clinical Trial Not Allowed)
Close date: October 8, 2027
|
|
|
|
|
|
